Team

Loredana Bucciarelli

Medico Endocrinologo

Curriculum

La dottoressa Loredana Bucciarelli è nata il 06/02/1972, da Marzo 2024 a oggi lavora presso la struttura Pio Albergo Trivulzio nell’Ambulatorio di Diabetologia e Malattie Metaboloche. Fatebenefratelli Sacco, S.S.D. Malattie 

Da Novembre 2016 al Settembre 2018 ha lavorato presso l’ IRCCS Ospedale San Raffaele – Diabetes Research Institute, Via Olgettina 60, Milano per lo sviluppo della ricerca “efficacia della Rapamicina e di un inibitore del DPP-4 nel migliorare la funzionalità beta-cellulare nel diabete di tipo 1 di lunga durata”

2011-febb 2024: Aiuto c/o IRCCS Multimedica nella unità operativa di Endocrinologia e diabetologia

Marzo 2024 ad oggi Ricercatrice c/o Università degli Studi di Milano c/o il Dipartimento di Scienze Biomediche e cliniche, settore concorsuale 06/02-Endocrinologia, nefrologia e Scienze della alimentazione e del Benessere, settore disciplinare MED/13-Endocrinologia trasformata in MEDS-08/A endocrinologia.

Attività assistenziale: Responsabile degli ambulatori di Diabetologia ed Endocrinologia

Lingue parlate

  • Italiano madre lingua
  • Inglese
  • Francese

Competenze tecniche

  • Utilizzo dei principali programmi informatici (Word, Excel, PowerPoint) in
    ambiente Windows e Macintosh.

Formazione

  • Training ICH/GCP: Partecipazione a 35 trials clinici

    ICH/GCP training on March 2015 : TBI Brookwood International Academy – ICH E6 GCP Investigator Site Training

    ICH/GCP Investigator Training version 1.3 June 2017 completed on August 2017.

    ICH/GCP E6(R2) with score 100% on 11/10/2024

  • 2011-febb 2024: Aiuto c/o IRCCS Multimedica nella unità operativa di Endocrinologia e diabetologia

  • Marzo 2024 ad oggi Ricercatrice c/o Università degli Studi di Milano c/o il Dipartimento di Scienze Biomediche e cliniche, settore concorsuale 06/02-Endocrinologia, nefrologia e Scienze della alimentazione e del Benessere, settore disciplinare MED/13-Endocrinologia trasformata in MEDS-08/A endocrinologia.

    Attività assistenziale: Responsabile degli ambulatori di Diabetologia ed Endocrinologia c/o il Pio Albergo Trivulzio

  • 2010: Assistente c/o IRCCS Istituto clinico Humanitas nella unità operativa di Endocrinologia e diabetologia

  • 2008-2009: Post-Doct research Fellow nel laboratorio di ricerca della Prof.ssa Ann Marie Schmidt

  • Ottobre 2005 e Novembre 2006 Corso di formazione di ecografia tiroidea e diagnostica interventistica (FNAB) c/o Arcispedale S. Maria Nuova Reggio Emilia

    2006-2009: Dottorato di ricerca in Scienze dell’invecchiamento presso l’Università degli studi di Chieti-Pescara. TitoloTesi: “Inflammatory Stress & Incipient Apoptosis in Primary Venous & Aortic Endothelia Cells of type 1 Diabetic mice” cum Laude

  • 2002-2006: Scuola di specializzazione in Endocrinologia e malattie del Ricambio, Università degli studi di Milano. (voto: 70/70 cum laude)

    Titolo Tesi: “No mutations in TPIT, a corticotroph-specific gene, in human tumoral pituitary ACTH-secreting cells”

  • 1999-2002: Esperienza clinica di ricerca nelle patologie vascolari presso la Columbia University di New York. Post-Doct research Fellow nel laboratorio di ricerca della Prof.ssa Ann Marie Schmidt

  • 1998: Conseguimento di Laurea in Medicina e Chirurgia presso l’Università degli Studi G. d’annunzio di Chieti (voto:110/110 cum laude)

    Titolo Tesi: La pompa Na/Li come marcatore per lo sviluppo della complicanza nefropatica nei pazienti affetti da DM1”

Pubblicazioni

  1. Bucciarelli L., Andreini D, Stefanini G, Fiorina RM, Francone M, Catapano f, Lunati ME, Conte e, Marchetti D, Fiorina P Pharmacologiacal regression of atherosclerotic plaque in patients with type 2 diabetes March 2025 vol 13, 107635 on line

2) D’Addio F, Lazzaroni E, Lunati ME, Preziosi G, Ercolanoni M, Turola G, Marrocu C, Cicconi G, Sharma S, Scarioni S, Montefusco L, Pastore I, Morpurgo PS, Rossi A, Gandolfi A, Tinari C, Rossi G, Ben Nasr M, Loretelli C, Fiorina RM, Grassa B, Terranova R, Bucciarelli L, Berra C, Cereda D, Zuccotti G, Borriello CR, Fiorina P. Vaccinome landscape in nearly 620,000 patients with diabetes. J Clin Endocrinol Metab. 2024 Jul 23:dgae476. doi: 10.1210/clinem/dgae476. Online ahead of print.PMID: 39040010

3) Lunati ME, Cimino V, Bernasconi D, Gandolfi A, Morpurgo PS, Tinari C, Lazzaroni E, Baruffaldi L, Muratori M, Montefusco L, Pastore I, Rossi A, Franzetti IG, Muratori F, Manfrini R, Disoteo OE, Terranova R, Desenzani P, Girelli A, Ghelardi R, D’Addio F, Ben Nasr M, Berra C, Folli F, Bucciarelli L, Fiorina P

Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. P.Pharmacol Res. 2024 Jan;199:107040. doi: 10.1016/j.phrs.2023.107040. Epub 2023 Dec 20.PMID: 38128857

4) Rossi A, Montefusco L, Reseghetti E, Pastore IF, Rossi G, Usuelli V, Loretelli C, Boci D, Ben Nasr M, D’Addio F, Bucciarelli L, Argenti S, Morpurgo P, Lunati ME, Fiorina P Daytime hypoglycemic episodes during the use of an advanced hybrid closed loop system  Diabetes Res Clin Pract. 2023 Dec;206:111011. doi: 10.1016/j.diabres.2023.111011. Epub 2023 Nov 11.PMID: 37956944

5) Berra C, Manfrini R, Mirani M, Bucciareli L., Zakari AS, Piccini S, Ghelardi R, Lunati ME, Rodovalho S, Bifari F,   Fiorina P, Folli F AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus. Acta Diabetol. 2023 Sep;60(9):1257-1266. doi: 10.1007/s00592-023-02115-x. Epub 2023 Jun 4.PMID: 37270748

6) Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study.

Pharmacol Res. 2022 Sep;183:106396. doi: 10.1016/j.phrs.2022.106396. Epub 2022 Aug 12.PMID: 35970329

7) Luzi L, Bucciarelli L, Ferrulli A, Terruzzi I, Massarini S Obesity and COVID-19: the ominous duet affecting the renin-angiotensin system.

Minerva Endocrinol (Torino). 2021 Jun;46(2):193-201. doi: 10.23736/S2724-6507.20.03402-1. Epub 2021 Jan 12.

8) Antonio NICOLUCCI 1✉, Giuseppe PROSPERINI 1, Raffaella BUZZETTI 2, Salvatore DE COSMO 3, Carmine G. FANELLI 4, Raffaele NAPOLI 5, Francesco GIORGINO 6, the AGERE Study Group  A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes

Minerva Endocrinologica 2018 December;43(4):501-10 DOI: 10.23736/S0391-1977.18.02850-X
9) Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12

10) Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall’Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society.

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

11) Rondinelli M, Rossi A, Gandolfi A, Saponaro F,Bucciarelli L, Adda G, Molinari C,      Montefusco L,   Specchia C, Chiara Rossi M, Scardapane M, Arosio M, Genovese S. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.

Clin Ther. 2017 Jan;39(1):159-169. doi: 10.1016/j.clinthera.2016.11.001. Epub 2016 Dec 9.

12) Bruttomesso D, Laviola L, Lepore G, Bonfanti R, Bozzetto L, Corsi A, Di Blasi V, Girelli A, Grassi G, Iafusco D, Rabbone I, Schiaffini R; Italian Study Group on Diffusion of CSII Continuous subcutaneous insulin infusion in Italy: third national survey. Diabetes Technol Ther. 2015 Feb;17(2):96-104. doi: 10.1089/dia.2014.0242. Epub 2014 Dec 5

13) Ceriello A, Esposito K, La Sala L, Pujadas G, De Nigris V, Testa R,Bucciarelli L, Rondinelli M, Genovese The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report..Cardiovasc Diabetol. 2014 Nov 19;13:140. doi: 10.1186/s12933-014-0140-9.

14) Ceriello A, Novials A, Canivell S, La Sala L, Pujadas G, Esposito K, Testa R,Bucciarelli L, Rondinelli M, Genovese Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes..Diabetes Care. 2014 Jul;37(7):1938-43. doi: 10.2337/dc13-2618. Epub 2014 Mar 25

15) Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G,Bucciarelli L, Rondinelli M, Genovese Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes.Diabetes Care. 2013 Dec;36(12):4104-8. doi: 10.2337/dc13-0750. Epub 2013 Oct 15. Erratum in: Diabetes Care. 2014 Jul;37(7):2063

16) Ceriello A, Novials A, Ortega E, Canivell S, Pujadas G, La Sala L,Bucciarelli L, Rondinelli M, Genovese Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes. S.Cardiovasc Diabetol. 2013 Jun 27;12:97. doi: 10.1186/1475-2840-12-97

17) Paolo C. Colombo, Duygu Onat, Ante Harxhi, Ryan t. Demmer, Yacki Hayashi, Sanja Jelic, Thierry H. LeJemtel, Loredana Bucciarelli, Moritz Kebschull, Panos Papapanou, nir Uriel, Ann Marie Schmidt, Hani N Sabbah, Ulrich P. JordePeripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J. 2014 Feb;35(7):448-54. doi: 10.1093/eurheartj/eht456. Epub 2013 Nov 20.

18) Loredana G. Bucciarelli, Andreas Pollreisz, Anjali Ganda, Moritz Kebschull,Enathia Lalla, Natasha Kalea, Barry Hudson, Ravichandran Ramasamy, Shi Fang, Paolo Colombo and Ann marie Schmidt Inflammatory Stress & Incipient Apoptosis in Primary Venous & Aortic Endothelia Cells of type 1 Diabetic mice. Diab Vasc Dis Res. 2009 Oct;6(4):249-61.

19) Moritz Kebschull, Loredana G. Bucciarelli, Ryan T. Demmer, Paolo C. Colombo, Panos N. Papapanou. Minimally invasive sampling and expression profiling of human vascular endothelium. Submitted to BMC Medicine

20) Santilli f, Vazzana N, Bucciarelli LG, Davi’ G. Soluble forms of RAGE in Human Disease: Clinical and therapeutical implications Curr med Chem 2009;16(8):940-52.

21) Loredana G. Bucciarelli, M.D., Radha Ananthakrishnan, PhD, Yuying C. Hwang, PhD, Michiyo Kaneko, PhD, Fei Song, DDS, David R. Sell, PhD, Christopher Strauch, Vincent M. Monnier, M.D., Shi Fang Yan, M.D., Ann Marie Schmidt, M.D., and Ravichandran Ramasamy, PhD Rage & modulation of ischemic injury in the diabetic myocardium. Diabetes April 2008 Diabetes. 2008 Jul;57(7):1941-51.

22) Santilli F, Bucciarelli L, Noto D, Cefalù AB, Davì V, Ferrante E, Pettinella C, Averna MR, Ciabattoni G, Davì G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med. 2007 Nov 1;43(9):1255-62.

23) Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, Clissa C, Ciabattoni G, Consoli A, Davì G.Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med. 2007 Aug 15;43(4):511-8. Epub 2007 Mar 24. PMID: 17640561

24) Pecori Giraldi F, Bucciarelli LG, Saccani A, Scacchi M, Pesce S, Losa M, Cavagnini F.Ghrelin stimulates adrenocorticotrophic hormone (ACTH) secretion by human ACTH-secreting pituitary adenomas in vitro.J Neuroendocrinol. 2007 Mar;19(3):208-12. PMID: 17280594

25) Lavezzi E, Fatti LM, Bucciarelli L, Bettinelli A, Scacchi M, Cavagnini F. Monolateral visual loss due to sphenoid sinus mucocele: a rare complication of transsphenoidal surgery. J Endocrinol Invest. 2006 Dec;29(11):1021-2. No abstract available. PMID: 17259802

26) Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, Song F, Qu W, Gomez T, Zou YS, Yan SF, Schmidt AM, Ramasamy R. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation. 2006 Mar 7;113(9):1226-34. Epub 2006 Feb 27.  PMID: 16505177

27) Bucciarelli LG, Pecori Giraldi F, Cavagnini F. No mutations in TPIT, a corticotroph-specific gene, in human tumoral pituitary ACTH-secreting cells. J Endocrinol Invest. 2005 Dec;28(11):1015-8. PMID: 16483181

28) Hudson BI, Wendt T, Bucciarelli LG, Rong LL, Naka Y, Yan SF, Schmidt AM. Diabetic vascular disease: it’s all the RAGE. Antioxid Redox Signal. 2005 Nov-              Dec;7(11-12):1588-600. Review.

29) Yan SF, Ramasamy R, Bucciarelli LG, Wendt T, Lee LK, Hudson BI, Stern DM, Lalla E, DU Yan S, Rong LL, Naka Y, Schmidt AM. RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res. 2004 May;1(1):10-20. Review.

30) Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Hörig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2916-24.

31) Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis. 2006 Mar;185(1):70-7. Epub 2005 Aug 1

32) Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM, Ramasamy R. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci. 2005 Jun;1043:702-9. Review. PMID: 16037296

33) Rong LL, Yan SF, Wendt T, Hans D, Pachydaki S, Bucciarelli LG, Adebayo A, Qu W, Lu Y, Kostov K, Lalla E, Yan SD, Gooch C, Szabolcs M, Trojaborg W, Hays AP, Schmidt AM. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways.FASEB J. 2004 Dec;18(15):1818-25.

34) Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM. RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1342-9. Epub 2004 May 20. Review.

35) Harja E, Bucciarelli LG, Lu Y, Stern DM, Zou YS, Schmidt AM, Yan SF. Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ Res. 2004 Feb 20;94(3):333-9. Epub 2003 Dec 11.

36) Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D’Agati V, Schmidt AM. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys. 2003 Nov 1;419(1):80-8. Review.

37) Lalla E, Lamster IB, Hofmann MA, Bucciarelli L, Jerud AP, Tucker S, Lu Y, Papapanou PN, Schmidt AM. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1405-11. Epub 2003 Jun 19.

38) Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D’Agati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003 Apr;162(4):1123-37.

39) Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002 Nov 26;106(22):2827-35.

40) Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci. 2002 Jul;59(7):1117-28. Review.

41) Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002 May;3(3):123-35.

42) Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep. 2002 May;4(3):228-37. Review.

43) Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM, Schmidt AM. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol. 2001 Aug;159(2):513-25.

44) Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D’Agati V, Pischetsrieder M, Stern DM, Schmidt AM. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):905-10.